Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Corvus Pharmaceuticals stock

Learn how to easily invest in Corvus Pharmaceuticals stock.

Corvus Pharmaceuticals Inc is a biotechnology business based in the US. Corvus Pharmaceuticals shares (CRVS) are listed on the NASDAQ and all prices are listed in US Dollars. Corvus Pharmaceuticals employs 28 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Corvus Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CRVS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Corvus Pharmaceuticals stock price (NASDAQ: CRVS)

Use our graph to track the performance of CRVS stocks over time.

Corvus Pharmaceuticals shares at a glance

Information last updated 2022-09-18.
Latest market close$0.74
52-week range$0.75 - $9.54
50-day moving average $0.98
200-day moving average $1.52
Wall St. target price$4.50
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.89

Buy Corvus Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Corvus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Corvus Pharmaceuticals price performance over time

Historical closes compared with the close of $0.74 from 2022-09-23

1 week (2022-09-16) -19.77%
1 month (2022-08-25) -28.85%
3 months (2022-06-24) -14.94%
6 months (2022-03-24) -55.42%
1 year (2021-09-24) -89.12%
2 years (2020-09-25) -81.55%
3 years (2019-09-25) 3.28
5 years (2017-09-25) 16.05

Corvus Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -18.42%
Return on equity TTM -41.37%
Profit margin 0%
Book value $1.73
Market capitalisation $42.9 million

TTM: trailing 12 months

Corvus Pharmaceuticals share dividends

We're not expecting Corvus Pharmaceuticals to pay a dividend over the next 12 months.

Corvus Pharmaceuticals share price volatility

Over the last 12 months, Corvus Pharmaceuticals's shares have ranged in value from as little as $0.75 up to $9.54. A popular way to gauge a stock's volatility is its "beta".

CRVS.US volatility(beta: 0.9)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corvus Pharmaceuticals's is 0.8961. This would suggest that Corvus Pharmaceuticals's shares are less volatile than average (for this exchange).

Corvus Pharmaceuticals overview

Corvus Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines.

Frequently asked questions

What percentage of Corvus Pharmaceuticals is owned by insiders or institutions?
Currently 3.719% of Corvus Pharmaceuticals shares are held by insiders and 55.359% by institutions.
How many people work for Corvus Pharmaceuticals?
Latest data suggests 28 work at Corvus Pharmaceuticals.
When does the fiscal year end for Corvus Pharmaceuticals?
Corvus Pharmaceuticals's fiscal year ends in December.
Where is Corvus Pharmaceuticals based?
Corvus Pharmaceuticals's address is: 863 Mitten Road, Burlingame, CA, United States, 94010
What is Corvus Pharmaceuticals's ISIN number?
Corvus Pharmaceuticals's international securities identification number is: US2210151005
What is Corvus Pharmaceuticals's CUSIP number?
Corvus Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 221015100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site